Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| APMAP | Q9HDC9 | Adipocyte plasma membrane-associated protein (Protein BSCv) | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Other mediation | 2 | 0.50 | |||
| AQP3 | Q92482 | Aquaporin-3 (AQP-3) (Aquaglyceroporin-3) | Blood group antigen proteinsMetabolic proteinsPlasma proteins | 6 | Fusion and delivery mediationMetabolism mediation | 2 | 0.50 | |||
| AQP5 | P55064 | Aquaporin-5 (AQP-5) | Disease related genesHuman disease related genesMetabolic proteins | 6 | Fusion and delivery mediation | 2 | 0.50 | |||
| ASTRA | Q96CP6 | Protein Aster-A (GRAM domain-containing protein 1A) | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Fusion and delivery mediation | 2 | 0.50 | |||
| AT12A | P54707 | Potassium-transporting ATPase alpha chain 2 (HK alpha 2) (Non-gastric H(+)/K(+) ATPase subunit alpha) (EC 7.2.2.19) (Non-gastric Na(+)/K(+) ATPase subunit alpha) (EC 7.2.2.13) (Proton pump) (Sodium pump) | EnzymesMetabolic proteinsPlasma proteins | 10 | Fusion and delivery mediation | 2 | 0.50 | |||
| AT135 | Q4VNC0 | Probable cation-transporting ATPase 13A5 (EC 7.2.2.-) (P5-ATPase isoform 5) | Predicted membrane proteins | 10 | Fusion and delivery mediationMetabolism mediation | 2 | 0.50 | |||
| AT2B4 | P23634 | Plasma membrane calcium-transporting ATPase 4 (PMCA4) (EC 7.2.2.10) (Matrix-remodeling-associated protein 1) (Plasma membrane calcium ATPase isoform 4) (Plasma membrane calcium pump isoform 4) | EnzymesFDA approved drug targetsMetabolic proteins | 10 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.50 | |||
| AT8B2 | P98198 | Phospholipid-transporting ATPase ID (EC 7.6.2.1) (ATPase class I type 8B member 2) (P4-ATPase flippase complex alpha subunit ATP8B2) | EnzymesMetabolic proteinsPredicted membrane proteins | 10 | Fusion and delivery mediation | 2 | 0.50 | |||
| ATP4B | P51164 | Potassium-transporting ATPase subunit beta (Gastric H(+)/K(+) ATPase subunit beta) (Proton pump beta chain) | FDA approved drug targetsMetabolic proteinsPredicted membrane proteins | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.50 | |||
| C2C2L | O14523 | Phospholipid transfer protein C2CD2L (C2 domain-containing protein 2-like) (C2CD2-like) (Transmembrane protein 24) | Predicted intracellular proteinsPredicted membrane proteinsTransporters | 1 | Fusion and delivery mediationMetabolism mediation | 2 | 0.50 | |||
| CAD15 | P55291 | Cadherin-15 (Cadherin-14) (Muscle cadherin) (M-cadherin) | Disease related genesHuman disease related genesPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 2 | 0.50 | |||
| CADH5 | P33151 | Cadherin-5 (7B4 antigen) (Vascular endothelial cadherin) (VE-cadherin) (CD antigen CD144) | Cancer-related genesCD markersPlasma proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationMetabolism mediation | 2 | 0.50 | |||
| CALRL | Q16602 | Calcitonin gene-related peptide type 1 receptor (CGRP type 1 receptor) (Calcitonin receptor-like receptor) (CRLR) | Disease related genesFDA approved drug targetsG-protein coupled receptors | 7 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 2 | 0.50 | |||
| CC107 | Q8WV48 | Coiled-coil domain-containing protein 107 | 1 | Other mediation | 2 | 0.50 | ||||
| CCR4 | P51679 | C-C chemokine receptor type 4 (C-C CKR-4) (CC-CKR-4) (CCR-4) (CCR4) (K5-5) (CD antigen CD194) | CD markersFDA approved drug targetsG-protein coupled receptors | 7 | AsthmaDiabetes mellitusImmune system disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.50 | ||
| CD28 | P10747 | T-cell-specific surface glycoprotein CD28 (TP44) (CD antigen CD28) | CD markersPredicted membrane proteins | 1 | Brain cancerDiabetes mellitusImmune system disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 2 | 0.50 | ||
| CD38 | P28907 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (EC 3.2.2.-) (EC 3.2.2.6) (2'-phospho-ADP-ribosyl cyclase) (2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase) (EC 2.4.99.20) (2'-phospho-cyclic-ADP-ribose transferase) (ADP-ribosyl cyclase 1) (ADPRC 1) (Cyclic ADP-ribose hydrolase 1) (cADPR hydrolase 1) (T10) (CD antigen CD38) | Cancer-related genesCD markersEnzymes | 1 | Acute myeloid leukaemiaB-cell lymphomaMalignant haematopoietic neoplasm | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.50 | ||
| CD3G | P09693 | T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g) | CD markersDisease related genesFDA approved drug targets | 1 | Breast cancerColorectal cancerMalignant digestive organ neoplasm | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.50 | ||
| CLC1A | Q8NC01 | C-type lectin domain family 1 member A (C-type lectin-like receptor 1) (CLEC-1) | 1 | Other mediation | 2 | 0.50 | ||||
| CLCA4 | Q14CN2 | Calcium-activated chloride channel regulator 4 (EC 3.4.-.-) (Calcium-activated chloride channel family member 4) (hCLCA4) (Calcium-activated chloride channel protein 2) (CaCC-2) (hCaCC-2) (Chloride channel accessory 4) [Cleaved into: Calcium-activated chloride channel regulator 4, 110 kDa form; Calcium-activated chloride channel regulator 4, 30 kDa form] | Predicted membrane proteinsTransporters | 1 | Fusion and delivery mediation | 2 | 0.50 | |||
| CLCN6 | P51797 | H(+)/Cl(-) exchange transporter 6 (Chloride channel protein 6) (ClC-6) (Chloride transport protein 6) | Disease related genesPlasma proteinsPredicted membrane proteins | 10 | Clinical-translation mediationFusion and delivery mediation | 2 | 0.50 | |||
| CLM7 | A8K4G0 | CMRF35-like molecule 7 (CLM-7) (CD300 antigen-like family member B) (CMRF35-A2) (Immune receptor expressed on myeloid cells 3) (IREM-3) (Leukocyte mono-Ig-like receptor 5) (Triggering receptor expressed on myeloid cells 5) (TREM-5) (CD antigen CD300b) | 1 | Immune mediation | 2 | 0.50 | ||||
| CLM8 | Q9UGN4 | CMRF35-like molecule 8 (CLM-8) (CD300 antigen-like family member A) (CMRF-35-H9) (CMRF35-H9) (CMRF35-H) (IRC1/IRC2) (Immunoglobulin superfamily member 12) (IgSF12) (Inhibitory receptor protein 60) (IRp60) (NK inhibitory receptor) (CD antigen CD300a) | CD markersPlasma proteinsPredicted intracellular proteins | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 2 | 0.50 | |||
| CNR1 | P21554 | Cannabinoid receptor 1 (CB-R) (CB1) (CANN6) | Disease related genesFDA approved drug targetsG-protein coupled receptors | 7 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.50 | |||
| CYBC1 | Q9BQA9 | Cytochrome b-245 chaperone 1 (Essential for reactive oxygen species protein) (Eros) | Disease related genesHuman disease related genesPredicted intracellular proteins | 1 | Other mediation | 2 | 0.50 |